William Tanner

Aegerion Drug Wins Panel Support for Cholesterol Disease

Aegerion Pharmaceuticals Inc. gained the support of U.S. advisers for its drug to treat the most life-threatening forms of high cholesterol. The shares rose 9 percent.

Aegerion Shares Rise on Report of High Cholesterol Drug

Aegerion Pharmaceuticals Inc. rose after a U.S. regulatory staff report said a plan to manage the risks of the company’s drug supports its approval in adults with the most life-threatening forms of severely high cholesterol.

Toddlers Facing Heart Attacks Await Ruling on New Drugs

Like any patient at risk of a heart attack, Kennedi Thompson has been counseled by her doctor to eat a low-fat diet and take prescription statins to reduce her cholesterol. Unlike most others facing heart disease, Kennedi is 3 years old.

Affymax Jumps Most in 16 Months on FDA Anemia-Drug Review

Affymax Inc. surged the most in 16 months after U.S. regulators said the company’s experimental anemia medicine works as well as drugs sold by Amgen Inc. and Johnson & Johnson for patients with chronic kidney disease.

Jazz Fibromyalgia Drug With Date Rape Chemical Is Safe, FDA Staff Say

Jazz Pharmaceuticals Inc. ’s fibromyalgia drug is safe and effective, said U.S. regulators weighing whether to approve the medicine, which includes a chemical linked to date rape.

Icahn Nominates Four for Forest Board in Second Fight

Investor Carl Icahn nominated four directors to the board of Forest Laboratories Inc. in a second proxy fight against the drugmaker.

Jazz Rebuffed on Pain Drug With Date-Rape Chemical

Jazz Pharmaceuticals Inc. tumbled the most in 19 months in Nasdaq Stock Market trading after failing to win a U.S. panel’s backing for a fibromyalgia drug that contains a chemical linked to date rape.

Affymax Wins U.S. Panel’s Backing on Anemia Drug to Rival Amgen’s Medicine

Affymax Inc. won a U.S. panel’s backing for an experimental anemia medicine that would compete with treatments marketed by Amgen Inc. and Johnson & Johnson for patients with chronic kidney disease.

Affymax Rises After Winning Panel’s Backing for Anemia Drug

Affymax Inc. surged the most in 16 months after winning a U.S. advisory panel’s backing for an experimental anemia medicine that would compete with treatments marketed by Amgen Inc. and Johnson & Johnson.

Vivus Fails to Win U.S. Approval for Diet Pill Qnexa Over Safety Concerns

Vivus Inc. failed to win U.S. approval to introduce the first new prescription diet pill in more than a decade, becoming the second experimental obesity treatment rejected by regulators in the past two weeks.

"It was there and then it was just gone."

- William Tanner on Dec 13, 2010

New York

California

Food And Drug Administration

Palo Alto

U.S. Stocks Jump After Better-Than-Forecast Jobs Data

Apple Said to Sign Sony Music, Clearing Way for IRadio

Gold Traders Most Bullish Since Bear Market Began: Commodities

Payrolls in U.S. Rose 175,000 in May, Unemployment 7.6%

Prince Philip ‘Progressing Satisfactorily’ After Surgery